R&D News | pharmaphorum

Friday 3 April 2026

News

News

Agios HQ

Agios shares slump on sickle cell disease data

Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.

News

US vulnerable to China's API dominance, says report

US vulnerable to China's API dominance, says report

China has such a dominant position in pharmaceutical ingredient production that there is a risk it will weaponise access, says a Congressional report.

News

GSK pumps £45m into antimicrobial resistance projects

GSK pumps £45m into antimicrobial resistance projects

GSK has revealed the six projects it will fund with the Fleming Initiative on antimicrobial resistance, set up with Imperial College London last year.

News

Roche extols 'unprecedented' result with breast cancer drug

Roche extols 'unprecedented' result with breast cancer drug

Roche's oral SERD giredestrant has achieved what the company says is a stellar result as adjuvant treatment for early breast cancer.

News

EBAI schematic

New guidance covers AI-based biomarkers for cancer care

ESMO guidance on the validation and clinical use of AI-based biomarkers in oncology aims to strike a balance between caution and over-reliance.

News

Halda Therapeutics' president and chief executive, Christian Schade

J&J swoops on cancer biotech Halda with $3bn takeover deal

Johnson & Johnson has added to the flurry of M&A deals in pharma with an agreement to buy Halda Therapeutics and its RIPTAC anticancer platform.